Research progress in tumor angiogenesis and drug resistance in breast cancer  

作　　者：Jiancheng Mou Chenhong Li Qinghui Zheng Xuli Meng Hongchao Tang 

机构地区：[1]The Second Clinical Medical College,Zhejiang Chinese Medical University,Hangzhou 310053,China [2]Department of Breast Surgery,General Surgery,Cancer Center,Zhejiang Provincial People's Hospital(Affiliated People's Hospital),Hangzhou Medical College,Hangzhou 310053,China [3]Key Laboratory for Diagnosis and Treatment of Upper Limb Edema and Stasis of Breast Cancer,Hangzhou310053,China

出　　处：《Cancer Biology & Medicine》2024年第7期571-585,共15页癌症生物学与医学（英文版）

基　　金：supported by the National Natural Science Foundation of China (Grant No. 81973861);Zhejiang Provincial Ministry Medical and Health Co-construction Major Project (Grant No. 20214355173);Zhejiang Science and Technology Department“Vanguard”“Leading Goose”research (Grant No. 2023C03044);Zhejiang Provincial Health“Leading Talents”Project;Zhejiang Medical and Health Science and Technology Project (Grant No. 2022KY558)。

摘　　要：Angiogenesis is considered a hallmark pathophysiological process in tumor development. Aberrant vasculature resulting from tumor angiogenesis plays a critical role in the development of resistance to breast cancer treatments, via exacerbation of tumor hypoxia, decreased effective drug concentrations within tumors, and immune-related mechanisms. Antiangiogenic therapy can counteract these breast cancer resistance factors by promoting tumor vascular normalization. The combination of antiangiogenic therapy with chemotherapy, targeted therapy, or immunotherapy has emerged as a promising approach for overcoming drug resistance in breast cancer. This review examines the mechanisms associated with angiogenesis and the interactions among tumor angiogenesis, the hypoxic tumor microenvironment, drug distribution, and immune mechanisms in breast cancer. Furthermore, this review provides a comprehensive summary of specific antiangiogenic drugs, and relevant studies assessing the reversal of drug resistance in breast cancer. The potential mechanisms underlying these interventions are discussed, and prospects for the clinical application of antiangiogenic therapy to overcome breast cancer treatment resistance are highlighted.

关 键 词：ANGIOGENESIS breast cancer CHEMOTHERAPY drug resistance vascular normalization immunologic therapy tumor microenvironment(TME) 

分 类 号：R737.9[医药卫生—肿瘤]